Given the advantages of available tissues, consistent management, well-controlled data quality by continuous involvement of investigators throughout the study as a single institution study and an optimal two-armed design by including a control group for evaluating the predictive values, this study aimed to investigate the predictive values of potential biomarkers such as tumor PD-L1 expression, tumor MSI status, tumor EBV infection, TMB, blood NLR, and serum Na to provide objective guidance in identifying patients with clinical benefits to nivolumab. This evidence concerns the gene CD274 and Epstein-Barr virus infection.